MedTrace Logo

Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis

NCT02482129 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).

Conditions

  • Acute Anterior Uveitis

Interventions

DRUG

LME636 60 mg/mL ophthalmic solution

DRUG

Dexamethasone 0.1% ophthalmic solution

DRUG

LME636 Vehicle

Inactive ingredients used for masking purposes

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Scientist NIBR, Alcon · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-17
Primary Completion
2016-03-21
Completion
2016-03-21

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482129 on ClinicalTrials.gov